Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

7(87.5%)

Phase 1

1(12.5%)

8Total

Phase 2(7)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04146896Phase 2Completed

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

Role: lead

NCT04147858Phase 2Completed

Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

Role: lead

NCT05181995Phase 2Terminated

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

Role: lead

NCT04148391Phase 2Active Not Recruiting

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

Role: lead

NCT03249103Phase 2Completed

Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

Role: lead

NCT04044664Phase 2Completed

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Role: lead

NCT03219320Phase 2Completed

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Role: lead

NCT02834741Phase 1Completed

Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

Role: lead

All 8 trials loaded